Astellas, Partner Aveo Rejected By U.S. FDA Panel For Kidney Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and its non-Asia development partner Aveo Pharmaceuticals received a no vote from a U.S. FDA advisory committee for the Japan drug maker's tivozanib for treating kidney cancer.